Cargando…
Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer
INTRODUCTION: Aromatase inhibitors (AIs) dramatically increased breast cancer (BC) survival, leading to enhanced attention to their long-term consequences on psychological functioning. Conflicting data has been examined regarding the association between AIs administration and the clinical psychologi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098625/ https://www.ncbi.nlm.nih.gov/pubmed/32214378 http://dx.doi.org/10.1371/journal.pone.0230681 |
_version_ | 1783511214893039616 |
---|---|
author | Martino, Gabriella Catalano, Antonino Agostino, Rita Maria Bellone, Federica Morabito, Nunziata Lasco, Carmen Giulia Vicario, Carmelo Mario Schwarz, Peter Feldt-Rasmussen, Ulla |
author_facet | Martino, Gabriella Catalano, Antonino Agostino, Rita Maria Bellone, Federica Morabito, Nunziata Lasco, Carmen Giulia Vicario, Carmelo Mario Schwarz, Peter Feldt-Rasmussen, Ulla |
author_sort | Martino, Gabriella |
collection | PubMed |
description | INTRODUCTION: Aromatase inhibitors (AIs) dramatically increased breast cancer (BC) survival, leading to enhanced attention to their long-term consequences on psychological functioning. Conflicting data has been examined regarding the association between AIs administration and the clinical psychological features in BC survivors (BCSs). PURPOSE: As psychological symptoms often occur in such chronic diseases, our study aimed at exploring anxious and depressive symptoms and the perceived quality of life (QoL) in BCSs assessed for osteoporosis. METHODS: The total sample consisted of a clinical sample of 51 outpatient postmenopausal women, diagnosed with BC, and a control group composed of 51 healthy postmenopausal women. All recruited participants were evaluated through the clinical gold standard interview and completed the following self-rating scales: the Hamilton Anxiety Rating Scale, Beck Depression Inventory II edition, and 36-Item Short Form Health Survey, which were administered at baseline and after 6 months in BCSs in AIs treatment, compared with controls. Moreover, all participants were assessed for vitamin D status, bone mineral density (BMD) and subclinical vertebral fractures. Data regarding age, age at menopause, body mass index (BMI), smoking habits and alcohol consumption was collected. RESULTS: BCSs (n = 51) showed higher anxious and depressive symptoms, and lower perceived QoL vs. controls (n = 51) (p<0.05 for all). After 6 months of treatment with AIs, BCSs showed significant reduction of anxious and depressive symptoms and a significantly higher perceived QoL for both physical and mental components, vs. controls. CONCLUSIONS: The improvement of clinical psychological features and perceived QoL was associated with AIs treatment in women being treated with, for early breast cancer. Further studies are needed to obtain a deeper comprehension of the correlation between clinical psychological and physical features in BCSs. |
format | Online Article Text |
id | pubmed-7098625 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-70986252020-04-03 Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer Martino, Gabriella Catalano, Antonino Agostino, Rita Maria Bellone, Federica Morabito, Nunziata Lasco, Carmen Giulia Vicario, Carmelo Mario Schwarz, Peter Feldt-Rasmussen, Ulla PLoS One Research Article INTRODUCTION: Aromatase inhibitors (AIs) dramatically increased breast cancer (BC) survival, leading to enhanced attention to their long-term consequences on psychological functioning. Conflicting data has been examined regarding the association between AIs administration and the clinical psychological features in BC survivors (BCSs). PURPOSE: As psychological symptoms often occur in such chronic diseases, our study aimed at exploring anxious and depressive symptoms and the perceived quality of life (QoL) in BCSs assessed for osteoporosis. METHODS: The total sample consisted of a clinical sample of 51 outpatient postmenopausal women, diagnosed with BC, and a control group composed of 51 healthy postmenopausal women. All recruited participants were evaluated through the clinical gold standard interview and completed the following self-rating scales: the Hamilton Anxiety Rating Scale, Beck Depression Inventory II edition, and 36-Item Short Form Health Survey, which were administered at baseline and after 6 months in BCSs in AIs treatment, compared with controls. Moreover, all participants were assessed for vitamin D status, bone mineral density (BMD) and subclinical vertebral fractures. Data regarding age, age at menopause, body mass index (BMI), smoking habits and alcohol consumption was collected. RESULTS: BCSs (n = 51) showed higher anxious and depressive symptoms, and lower perceived QoL vs. controls (n = 51) (p<0.05 for all). After 6 months of treatment with AIs, BCSs showed significant reduction of anxious and depressive symptoms and a significantly higher perceived QoL for both physical and mental components, vs. controls. CONCLUSIONS: The improvement of clinical psychological features and perceived QoL was associated with AIs treatment in women being treated with, for early breast cancer. Further studies are needed to obtain a deeper comprehension of the correlation between clinical psychological and physical features in BCSs. Public Library of Science 2020-03-26 /pmc/articles/PMC7098625/ /pubmed/32214378 http://dx.doi.org/10.1371/journal.pone.0230681 Text en © 2020 Martino et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Martino, Gabriella Catalano, Antonino Agostino, Rita Maria Bellone, Federica Morabito, Nunziata Lasco, Carmen Giulia Vicario, Carmelo Mario Schwarz, Peter Feldt-Rasmussen, Ulla Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer |
title | Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer |
title_full | Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer |
title_fullStr | Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer |
title_full_unstemmed | Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer |
title_short | Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer |
title_sort | quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098625/ https://www.ncbi.nlm.nih.gov/pubmed/32214378 http://dx.doi.org/10.1371/journal.pone.0230681 |
work_keys_str_mv | AT martinogabriella qualityoflifeandpsychologicalfunctioninginpostmenopausalwomenundergoingaromataseinhibitortreatmentforearlybreastcancer AT catalanoantonino qualityoflifeandpsychologicalfunctioninginpostmenopausalwomenundergoingaromataseinhibitortreatmentforearlybreastcancer AT agostinoritamaria qualityoflifeandpsychologicalfunctioninginpostmenopausalwomenundergoingaromataseinhibitortreatmentforearlybreastcancer AT bellonefederica qualityoflifeandpsychologicalfunctioninginpostmenopausalwomenundergoingaromataseinhibitortreatmentforearlybreastcancer AT morabitonunziata qualityoflifeandpsychologicalfunctioninginpostmenopausalwomenundergoingaromataseinhibitortreatmentforearlybreastcancer AT lascocarmengiulia qualityoflifeandpsychologicalfunctioninginpostmenopausalwomenundergoingaromataseinhibitortreatmentforearlybreastcancer AT vicariocarmelomario qualityoflifeandpsychologicalfunctioninginpostmenopausalwomenundergoingaromataseinhibitortreatmentforearlybreastcancer AT schwarzpeter qualityoflifeandpsychologicalfunctioninginpostmenopausalwomenundergoingaromataseinhibitortreatmentforearlybreastcancer AT feldtrasmussenulla qualityoflifeandpsychologicalfunctioninginpostmenopausalwomenundergoingaromataseinhibitortreatmentforearlybreastcancer |